Back to results
US 7,662,378 B2Granted
Antibody therapy
AssigneeImmunomedics, Inc.
InventorsDavid M. Goldenberg, Hans J. Hansen
Life of this patent
Estimating the term…
Abstract
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
Claims18
A method for treating a CEA and/or NCA expressing carcinoma comprising:
- a) administering to a subject with a CEA and/or NCA expressing carcinoma a monovalent Class I anti-CEA monoclonal antibody (MAb) or antigen-binding fragment thereof, wherein the MAb or fragment thereof is a monovalent chimeric or humanized MN-3 or MN-15 antibody;
- and
- b) administering either concurrently or sequentially at least one anti-cancer therapeutic agent.
A method for treating a CEA and/or NCA expressing carcinoma comprising:
- a) administering to a subject with a CEA and/or NCA expressing carcinoma a monovalent Class I anti-CEA monoclonal antibody (MAb) or antigen-binding fragment thereof, wherein said antibody fragment is selected from the group consisting of a Fab′, a Fab, an Fv and an scFv;
- and
- b) administering either concurrently or sequentially at least one anti-cancer therapeutic agent.
Dependencies are inferred from the claim text.